Exelixis, Inc. (NASDAQ:EXEL) announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held June 1-5, 2012, in Chicago, Illinois. Clinical data for cabozantinib will be featured in four oral presentations, four poster discussion presentations, and one general poster presentation. For the first time, investigators will present data from EXAM, the pivotal trial of cabozantinib in medullary thyroid cancer. Initial positive top-line results from EXAM were announced in October 2011.
“The nine data presentations at this year’s ASCO Annual Meeting are indicative of the growing depth and breadth of cabozantinib’s global clinical development program,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “As the data across multiple tumor types for cabozantinib continues to mature, its unique activity profile is increasingly being recognized broadly across the oncology community. We look forward to sharing these exciting data at ASCO later this year.”
The full roster of cabozantinib data presentations expected at the meeting (all times Central Daylight Time):
- “Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)” (Abstract #4006)Dr. Chris Verslype, Hepatology, University Hospitals Gasthuisberg, BelgiumOral Abstract Session: Gastrointestinal (Noncolorectal) CancerSaturday, June 2; 3:00 p.m. – 6:00 p.m.
- “Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)” (Abstract #4504)Dr. Toni K. Choueiri, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MAOral Abstract Session: Genitourinary Cancer (Nonprostate)Saturday, June 2; 3:00 p.m. – 6:00 p.m.
- “An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline” (Abstract #5508)Dr. Patrick Schöffski, Department of General Medical Oncology, Catholic University Leuven, BelgiumClinical Science Symposium : Targeting Therapeutics for Thyroid CancersMonday, June 4; 11:30 a.m. – 1:00 p.m.
- “Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)” (Abstract #4513)Dr. Matthew R. Smith, Massachusetts General Hospital Cancer Center, Boston, MAOral Abstract Session: Genitourinary Cancer (Prostate)Tuesday, June 5; 9:45 a.m. – 12:45 p.m.
- “Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)” (Abstract #535)Dr. Eric P. Winer, Dana-Farber Cancer Institute, Boston, MAPoster Discussion Session: Breast Cancer-HER2/ERSaturday, June 2; 1:15 p.m. – 5:45 p.m.
- “Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)” (Abstract #8531)Dr. Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZPoster Discussion Session: Melanoma/Skin CancersSaturday, June 2; 1:15 p.m. – 5:45 p.m.
- “Investigator sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases” (Abstract #4566)Dr. Richard J. Lee, Massachusetts General Hospital Cancer Center, Boston, MAPoster Discussion Session: Genitourinary (Prostate) CancerMonday, June 4, 8:00 a.m. – 12:30 p.m.
- “Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT)” (Abstract #7514)Dr. Beth A. Hellerstedt, US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Texas Oncology, Central Austin Cancer Center, Austin, TXPoster Discussion Session: Lung Cancer - Non-small Cell MetastaticTuesday, June 5; 8:00 a.m. – 12:30 p.m.
- “Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC)” (Abstract #5547)Dr. Maria E. Cabanillas, University of Texas M. D. Anderson Cancer Center, Houston, TXGeneral Poster Session: Head and Neck CancerSaturday, June 2; 1:15 p.m. – 5:15 p.m.
- Extensive apoptosis of malignant cells
- Decreased tumor invasiveness and metastasis
- Decreased tumor and endothelial cell proliferation
- Blockade of metastatic bone lesion progression
- Disruption of tumor vasculature
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV